Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men

European Urology

Volumn 39, Issue 1, 2001, Pages 36-41

  Øverland, Geir B ^a   Vatten, Lars ^b   Rhodes, Thomas ^a   Demuro, Carla ^c   Jacobsen, Geir ^b   Vada, Karsten ^d   Angelsen, Anders ^a   Girman, Cynthia J ^c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Innherred Hospital   (Norway)

Author keywords

Community based study; Epidemiology; Lower urinary tract symptoms; Prevalence; Prostatic hypertrophy

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; NORWAY; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY; URETHRA; URINE FLOW RATE;

AGED; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; NORWAY; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; URINATION DISORDERS; URODYNAMICS;

EID: 0035135424     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052410     Document Type: Article

References (32)

1. New words for old: Lower urinary tract symptoms for 'prostatism'
2. The prostate and the endocrines: A control series
3. Natural history of benign prostatic hypertrophy
4. Epidemiology and natural history of benign prostatic hyperplasia
5. High prevalence of benign prostatic hypertrophy in the community
6. The prevalence of prostatism: A population-based survey of urinary symptoms
7. Prevalence of prostatism in Japanese men in a population-based study with comparison to a similar American study
8. Prevalence of benign prostatic hyperplasia in Spanish men 40 years or older
9. International comparison of the community prevalence of symptoms of prostatism in four countries
10. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years or older
11. Results of an epidemiological survey using a modified American Urological Associations symptom index for benign prostatic hyperplasia in France
12. Urinary symptoms: Prevalence and severity in British men aged 55 and over
13. The International Prostate Symptom Score in a community-based sample of men between fifty-five and seventy-four years of age. Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume
14. Recommendations of the International Consensus Committee concerning: 1. Prostate symptom score and quality of life assessment
15. Ten language translation and harmonization of the International Prostate Symptom Score: Developing a methodology for multinational clinical trials
16. Validation of a new quality of life questionnaire for benign prostatic hyperplasia
17. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association
18. Assessment of volume measurement of the prostate using per-rectal ultrasonography
19. The ultrasound cystody-namogram - A new radiological technique
20. The accuracy of ultrasound in the measurement of changes in bladder volume
21. Micturition in the normal male
22. Does mode of administration affect the reporting of urinary symptoms?
23. Adverse effects of medications of urinary symptoms and flow rate: A community-based study
24. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men - Results of community-based studies in two countries
25. Natural history of prostatism: Urinary flow rates in a community-based study
26. Natural history and epidemiology of benign prostatic hyperplasia: Relationship among urologic measures
27. Parameters of prostate volume and shape in a community-based population of men 55 to 74 years old
28. The natural history of prostatism: The effects of non-response bias
29. Natural history of prostatism: Risk factors for urinary retention
30. Treatment for benign prostatic hyperplasia among community-dwelling men: The Olmsted County Study of urinary symptoms and health status among men
31. Natural history of BPH: Longitudinal prostate growth rates during five years in randomly selected community men 40 to 79 years old
32. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges